BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34831159)

  • 1. Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma.
    Van Loenhout J; Freire Boullosa L; Quatannens D; De Waele J; Merlin C; Lambrechts H; Lau HW; Hermans C; Lin A; Lardon F; Peeters M; Bogaerts A; Smits E; Deben C
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.
    Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C
    Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menadione Potentiates Auranofin-Induced Glioblastoma Cell Death.
    Szeliga M; Rola R
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells.
    Kato I; Kasukabe T; Kumakura S
    Int J Oncol; 2020 Oct; 57(4):1057-1071. PubMed ID: 32945449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Auranofin Synergizes with the PARP Inhibitor Olaparib to Induce ROS-Mediated Cell Death in Mutant p53 Cancers.
    Freire Boullosa L; Van Loenhout J; Flieswasser T; Hermans C; Merlin C; Lau HW; Marcq E; Verschuuren M; De Vos WH; Lardon F; Smits ELJ; Deben C
    Antioxidants (Basel); 2023 Mar; 12(3):. PubMed ID: 36978917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morin enhances auranofin anticancer activity by up-regulation of DR4 and DR5 and modulation of Bcl-2 through reactive oxygen species generation in Hep3B human hepatocellular carcinoma cells.
    Hwang-Bo H; Lee WS; Nagappan A; Kim HJ; Panchanathan R; Park C; Chang SH; Kim ND; Leem SH; Chang YC; Kwon TK; Cheong JH; Kim GS; Jung JM; Shin SC; Hong SC; Choi YH
    Phytother Res; 2019 May; 33(5):1384-1393. PubMed ID: 30887612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo.
    Fan C; Zheng W; Fu X; Li X; Wong YS; Chen T
    Cell Death Dis; 2014 Apr; 5(4):e1191. PubMed ID: 24763048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered antioxidant system stimulates dielectric barrier discharge plasma-induced cell death for solid tumor cell treatment.
    Kaushik NK; Kaushik N; Park D; Choi EH
    PLoS One; 2014; 9(7):e103349. PubMed ID: 25068311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation.
    Radenkovic F; Holland O; Vanderlelie JJ; Perkins AV
    Biochem Pharmacol; 2017 Dec; 146():42-52. PubMed ID: 28947276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting redox homeostasis in rhabdomyosarcoma cells: GSH-depleting agents enhance auranofin-induced cell death.
    Habermann KJ; Grünewald L; van Wijk S; Fulda S
    Cell Death Dis; 2017 Oct; 8(10):e3067. PubMed ID: 28981107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auranofin radiosensitizes tumor cells through targeting thioredoxin reductase and resulting overproduction of reactive oxygen species.
    Wang H; Bouzakoura S; de Mey S; Jiang H; Law K; Dufait I; Corbet C; Verovski V; Gevaert T; Feron O; Van den Berge D; Storme G; De Ridder M
    Oncotarget; 2017 May; 8(22):35728-35742. PubMed ID: 28415723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
    Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
    Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystatin SN inhibits auranofin-induced cell death by autophagic induction and ROS regulation via glutathione reductase activity in colorectal cancer.
    Oh BM; Lee SJ; Cho HJ; Park YS; Kim JT; Yoon SR; Lee SC; Lim JS; Kim BY; Choe YK; Lee HG
    Cell Death Dis; 2017 Mar; 8(3):e2682. PubMed ID: 28300829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of auranofin-induced apoptosis in MCF-7 human breast cells by selenocystine, a synergistic inhibitor of thioredoxin reductase.
    Liu C; Liu Z; Li M; Li X; Wong YS; Ngai SM; Zheng W; Zhang Y; Chen T
    PLoS One; 2013; 8(1):e53945. PubMed ID: 23342042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of intracellular and extracellular ROS formation in apoptosis induced by cold atmospheric helium plasma and X-irradiation in the presence of sulfasalazine.
    Moniruzzaman R; Rehman MU; Zhao QL; Jawaid P; Mitsuhashi Y; Imaue S; Fujiwara K; Ogawa R; Tomihara K; Saitoh JI; Noguchi K; Kondo T; Noguchi M
    Free Radic Biol Med; 2018 Dec; 129():537-547. PubMed ID: 30355525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways.
    Bijangi-Vishehsaraei K; Reza Saadatzadeh M; Wang H; Nguyen A; Kamocka MM; Cai W; Cohen-Gadol AA; Halum SL; Sarkaria JN; Pollok KE; Safa AR
    J Neurosurg; 2017 Dec; 127(6):1219-1230. PubMed ID: 28059653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-talk between two antioxidants, thioredoxin reductase and heme oxygenase-1, and therapeutic implications for multiple myeloma.
    Raninga PV; Di Trapani G; Vuckovic S; Tonissen KF
    Redox Biol; 2016 Aug; 8():175-85. PubMed ID: 26795735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SK channel activation potentiates auranofin-induced cell death in glio- and neuroblastoma cells.
    Krabbendam IE; Honrath B; Bothof L; Silva-Pavez E; Huerta H; Peñaranda Fajardo NM; Dekker F; Schmidt M; Culmsee C; César Cárdenas J; Kruyt F; Dolga AM
    Biochem Pharmacol; 2020 Jan; 171():113714. PubMed ID: 31738894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma.
    Cultrara C; Uhl C; Kirby K; Abed Elrazaq E; Zellander A; Andrews DW; Scott CB; Galluzzi L; Exley MA; Zilberberg J
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37550054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro antineoplastic effects of auranofin in canine lymphoma cells.
    Zhang H; Rose BJ; Pyuen AA; Thamm DH
    BMC Cancer; 2018 May; 18(1):522. PubMed ID: 29724201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.